Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$1.88 -1.6%	$2.17	$1.29 ▼ $7.85	$206.26M	1.24	1.82 million shs	865,808 shs
GOSS Gossamer Bio	$0.96 -2.1%	$1.10	$0.50 ▼ $1.55	$217.75M	1.88	1.58 million shs	2.46 million shs
IPSC Century Therapeutics	$0.50 -5.4%	$0.56	$0.34 ▼ $3.70	$45.62M	1.83	427,747 shs	639,514 shs
SOPH SOPHiA GENETICS	$3.16 +3.6%	$3.21	$2.58 ▼ $6.28	$203.40M	1.02	64,877 shs	21,717 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	+28.77%	-16.07%	-54.48%	-57.75%
GOSS Gossamer Bio	0.00%	+14.08%	-17.39%	+3.04%	+35.30%
IPSC Century Therapeutics	0.00%	-7.72%	-8.52%	-44.26%	-83.05%
SOPH SOPHiA GENETICS	0.00%	+11.66%	-14.13%	-24.76%	-37.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	2.1357 of 5 stars	3.5	1.0	0.0	3.1	1.7	0.6
GOSS Gossamer Bio	3.8475 of 5 stars	3.5	2.0	4.7	2.8	1.7	0.0
IPSC Century Therapeutics	2.1275 of 5 stars	3.5	1.0	0.0	3.1	1.7	0.6
SOPH SOPHiA GENETICS	2.4267 of 5 stars	3.4	5.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	3.00	Buy	$18.67	892.91% Upside
GOSS Gossamer Bio	3.00	Buy	$7.50	682.64% Upside
IPSC Century Therapeutics	3.00	Buy	$4.40	777.02% Upside
SOPH SOPHiA GENETICS	2.75	Moderate Buy	$6.80	115.19% Upside

Current Analyst Ratings Breakdown

Latest IPSC, SOPH, GOSS, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
4/3/2025	IPSC Century Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
3/28/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/24/2025	IPSC Century Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $7.00
3/21/2025	IPSC Century Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
3/20/2025	IPSC Century Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$4.00 ➝ $2.00
3/18/2025	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/14/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
3/6/2025	SOPH SOPHiA GENETICS	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
3/4/2025	ANNX Annexon	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
1/30/2025	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$3.20 per share	N/A
GOSS Gossamer Bio	$114.70M	1.90	N/A	N/A	$0.28 per share	3.42
IPSC Century Therapeutics	$6.59M	6.55	N/A	N/A	$3.06 per share	0.16
SOPH SOPHiA GENETICS	$65.17M	3.23	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$134.24M	-$1.02	N/A	N/A	N/A	N/A	-38.99%	-33.90%	5/12/2025 (Estimated)
GOSS Gossamer Bio	-$179.82M	-$0.26	N/A	N/A	N/A	N/A	-127.28%	-22.12%	5/6/2025 (Estimated)
IPSC Century Therapeutics	-$136.67M	-$1.63	N/A	N/A	N/A	-4,837.73%	-61.66%	-31.78%	5/8/2025 (Estimated)
SOPH SOPHiA GENETICS	-$78.98M	-$0.95	N/A	N/A	N/A	-110.71%	-55.06%	-38.33%	5/6/2025 (Estimated)

Latest IPSC, SOPH, GOSS, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ANNX Annexon	-$0.30	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	IPSC Century Therapeutics	-$0.31	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	GOSS Gossamer Bio	-$0.19	N/A	N/A	N/A	$3.95 million	N/A
5/6/2025	Q1 2025	SOPH SOPHiA GENETICS	-$0.21	N/A	N/A	N/A	$16.76 million	N/A
3/19/2025	Q4 2024	IPSC Century Therapeutics	-$0.45	-$0.43	+$0.02	-$0.43	$0.67 million	$4.18 million
3/18/2025	Q4 2024	GOSS Gossamer Bio	-$0.15	-$0.15	N/A	-$0.15	$7.02 million	$9.38 million
3/4/2025	Q4 2024	SOPH SOPHiA GENETICS	-$0.23	-$0.23	N/A	-$0.23	$17.71 million	$17.73 million
3/3/2025	Q4 2024	ANNX Annexon	-$0.28	-$0.33	-$0.05	-$0.33	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	17.17	17.18
GOSS Gossamer Bio	3.64	6.74	6.74
IPSC Century Therapeutics	N/A	10.39	10.39
SOPH SOPHiA GENETICS	0.12	3.80	3.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
GOSS Gossamer Bio	81.23%
IPSC Century Therapeutics	50.20%
SOPH SOPHiA GENETICS	31.59%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	12.67%
GOSS Gossamer Bio	5.00%
IPSC Century Therapeutics	6.80%
SOPH SOPHiA GENETICS	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.71 million	93.09 million	Optionable
GOSS Gossamer Bio	180	227.22 million	215.27 million	Optionable
IPSC Century Therapeutics	170	86.05 million	79.25 million	Optionable
SOPH SOPHiA GENETICS	520	66.69 million	62.19 million	Not Optionable

IPSC, SOPH, GOSS, and ANNX Headlines

Recent News About These Companies

SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

April 22, 2025 | prnewswire.com

Sophia Genetics, Precision for Medicine enter strategic partnership

April 9, 2025 | markets.businessinsider.com

Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities

April 8, 2025 | prnewswire.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

April 1, 2025 | marketbeat.com

SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?

March 21, 2025 | zacks.com

Morgan Stanley Keeps Their Hold Rating on SOPHiA GENETICS (SOPH)

March 20, 2025 | markets.businessinsider.com

SOPHiA GENETICS (SOPH) Gets a Buy from BTIG

March 18, 2025 | markets.businessinsider.com

SOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTC

March 18, 2025 | prnewswire.com

SOPHiA GENETICS (SOPH) Receives a Buy from BTIG

March 12, 2025 | markets.businessinsider.com

Baby Sophia from embryo swap will stay with birth parents court rules on appeal

March 11, 2025 | msn.com

District Court rules to keep IVF child with birth mother following embryo mix-up

March 10, 2025 | msn.com

Court overturns ruling that ordered toddler returned to genetic parents following embryo mix-up

March 10, 2025 | msn.com

Sophia Genetics price target lowered to $5 from $6 at BTIG

March 6, 2025 | markets.businessinsider.com

SOPHiA GENETICS (SOPH) Gets a Buy from RBC Capital

March 5, 2025 | markets.businessinsider.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2024 Earnings Call Transcript

March 5, 2025 | msn.com

SOPHiA GENETICS Full Year 2024 Earnings: In Line With Expectations

March 5, 2025 | finance.yahoo.com

SOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call Transcript

March 4, 2025 | seekingalpha.com

Sophia Genetics sees FY25 revenue $72M-$76M, consensus $74.51M

March 4, 2025 | markets.businessinsider.com

Craig-Hallum Sticks to Its Buy Rating for SOPHiA GENETICS (SOPH)

March 4, 2025 | markets.businessinsider.com

SOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue Estimates

March 4, 2025 | zacks.com

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 Results

March 4, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, SOPH, GOSS, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$1.88 -0.03 (-1.57%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$1.85 -0.03 (-1.81%)

As of 04/25/2025 07:58 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Gossamer Bio NASDAQ:GOSS

$0.96 -0.02 (-2.13%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$0.96 0.00 (-0.03%)

As of 04/25/2025 07:44 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Century Therapeutics NASDAQ:IPSC

$0.50 -0.03 (-5.38%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$0.52 +0.02 (+3.45%)

As of 04/25/2025 07:08 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

SOPHiA GENETICS NASDAQ:SOPH

$3.16 +0.11 (+3.61%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$3.12 -0.04 (-1.11%)

As of 04/25/2025 06:57 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time